25,052 results match your criteria Chronic Myelogenous Leukemia

["New treatments for chronic myelogenous leukemia"].

Rev Prat 2021 Mar;71(3):245-248

"Service d'hématologie clinique, hôpital Paul-Brousse, AP-HP, université Paris-Saclay, Villejuif, France".

View Article and Full-Text PDF

RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer.

J Cancer 2021 1;12(15):4616-4625. Epub 2021 Jun 1.

Hallym Translational Research Institute, Hallym University Sacred Heart Hospital, Anyang, 14066, Republic of Korea.

Abnormal regulation of genes has been closely related to gastric cancer. The characterization of gastric cancer has necessitated the development of new therapeutics as well as the identification of prognostic markers to predict the response to novel drugs. In our study, we used RNA sequencing analyses to show that on gastric cancer tissues to identification of gastric cancer prognostic markers. Read More

View Article and Full-Text PDF

Imatinib reduces the fertility of male mice by penetrating the blood-testis barrier and inducing spermatogonia apoptosis.

Reprod Biol 2021 Jun 16;21(3):100527. Epub 2021 Jun 16.

Department of Hematology, The 967th Hospital of Chinese People's Liberation Army, Liaoning, China. Electronic address:

Imatinib, the first generation of tyrosine kinase inhibitor, is used to treat and improve the prognosis of chronic myelogenous leukemia (CML). Clinical data suggest that imatinib could cross the blood-testis barrier and reduces the fertility of patients with CML-chronic phase. However, its exact molecular mechanism has not been fully elucidated. Read More

View Article and Full-Text PDF

CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.

Biochem Pharmacol 2021 Jun 17;190:114658. Epub 2021 Jun 17.

Department of Internal Medicine, Anam Hospital Korea University Medical Center, Seoul, South Korea. Electronic address:

Chronic myeloid leukemia (CML) is a reciprocal translocation disorder driven by a breakpoint cluster region (BCR)-Abelson leukemia virus (ABL) fusion gene that stimulates abnormal tyrosine kinase activity. Tyrosine kinase inhibitors (TKIs) are effective in treating Philadelphia chromosome (Ph) + CML patients. However, the appearance of TKI-resistant CML cells is a hurdle in CML treatment. Read More

View Article and Full-Text PDF

Structure-Based Design, Synthesis, and Evaluation of Anti-CML Activity of the Quinolinequinones as LY83583 Analogs.

Chem Biol Interact 2021 Jun 16:109555. Epub 2021 Jun 16.

Department of Chemistry, Faculty of Science, Istanbul University, Fatih, Istanbul, Turkey. Electronic address:

Quinone-based small molecules are the promising structures for antiproliferative drug design and can induce apoptosis in cancer cells. Among them, one of the quinolinequinones, entitled as 6-anilino-5,8-quinolinequinone, LY83583 has the ability to inhibit the growth of cancer cells as an inhibitor of cyclase. The biological potential of all synthesized compounds as the analogs of the identified lead molecule LY83583 that possessed the antiproliferative efficiency was determined. Read More

View Article and Full-Text PDF

Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line.

Leuk Res 2021 Jun 11;109:106641. Epub 2021 Jun 11.

School of Biotechnology, Institute of Science, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India. Electronic address:

Background: Drug resistance mechanisms are the regulatory factors associated with drug metabolism and drug transport to inward and outward of the target cells. Maybridge fragment (MBF) library is a collection of pharmacophore rich compounds having affinity with membrane transporters. This study has been designed to evaluate the efficacy of MBFs in overcoming the leukemic cells' resistance to imatinib. Read More

View Article and Full-Text PDF

DNA binding ability and cytotoxicity, cell cycle arrest and apoptosis inducing properties of a benzochromene derivative against K562 human leukemia cells.

Nucleosides Nucleotides Nucleic Acids 2021 Jun 15:1-22. Epub 2021 Jun 15.

Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.

Chromene and its derivatives are generally spread in nature. Heterocylic-based compounds like chromenes have displayed pharmacological activities. Chromene derivatives are critical due to some biological features such as anticancer activity. Read More

View Article and Full-Text PDF

Taking therapeutic apheresis services to patients in South Africa: An eight year review of SANBS mobile therapeutic apheresis service, 2013-2020.

Transfus Apher Sci 2021 May 21:103167. Epub 2021 May 21.

Sanquin Blood Supply, The Netherlands.

Introduction: A 20 year review of health and health care presents the multiple challenges faced by South Africans. Health and poverty is highlighted with 45% of population living on approximately US$ 2 per day and 10 million living on less than US$ 1 per day. Widening disparities in health care provision between public and private sector hospital services exist. Read More

View Article and Full-Text PDF

[Chronic-phase chronic myeloid leukemia with intracranial hemorrhage complicated with tumor lysis syndrome].

Rinsho Ketsueki 2021 ;62(5):346-351

Department of Hematology/Oncology, Saitama Children's Medical Center.

A 14-year-old male with autism was admitted to our hospital owing to altered consciousness and gait disturbance. Blood tests showed a white blood cell (WBC) count of 728,600/µl, and brain computed tomography revealed intracranial hemorrhage and a midline shift of the brain. The chronic phase of chronic myeloid leukemia (CML) was confirmed as per bone marrow aspiration findings. Read More

View Article and Full-Text PDF

Brefeldin A Induces Apoptosis, Inhibits BCR-ABL Activation, and Triggers BCR-ABL Degradation in Chronic Myeloid Leukemia K562 Cells.

Anticancer Agents Med Chem 2021 Jun 8. Epub 2021 Jun 8.

Key Laboratory of Marine Drugs, The Ministry of Education of China, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by BCR-ABL oncoprotein. Tyrosine kinase inhibitors have been developed to inhibit the activity of BCR-ABL; however, drug resistance and side effect occur in clinic application. Therefore, it is urgent to find novel drugs for CML treatment. Read More

View Article and Full-Text PDF

Implementation of DoE and Risk-Based Enhanced Analytical Quality by Design Approach to Stability Indicating RP-HPLC Method for Stability Study of Bosutinib.

J AOAC Int 2021 Jun 8. Epub 2021 Jun 8.

Department of Quality Assurance, Maliba Pharmacy College, UkaTarsadia University, Bardoli-Mahuva Road, Tarsadi, Mahuva, Surat-394 350, Gujarat, India.

Background: Bosutinib is a small molecule BCR-ABL, and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukaemia. According to published literature, no stability-indicating RP-HPLC method has been reported yet for estimation of bosutinib.

Objective: Hence, the stability-indicating RP-HPLC method has been developed for the stability study of bosutinib using risk and DoE-based enhanced analytical quality by design approach. Read More

View Article and Full-Text PDF

Nilotinib-Associated Atherosclerosis Presenting as Multifocal Intracranial Stenosis and Acute Stroke.

J Stroke Cerebrovasc Dis 2021 Jun 2;30(8):105883. Epub 2021 Jun 2.

Department of Neurology, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, NJ, United States.

Nilotinib, a BCR-ABL tyrosine kinase inhibitor (TKI), has been associated with vascular events and accelerated arterial stenosis, presumably of atherosclerotic etiology. Studies of nilotinib-associated atherosclerosis are mainly associated with progressive peripheral artery occlusive disease (PAOD), and only a few cases of coronary artery disease (CAD), and cerebrovascular disease (CVD) have been reported. The mechanisms by which nilotinib promotes atherosclerosis are poorly understood but endothelial and perivascular factors, mast cell depletion, and metabolic factors such as promotion of dyslipidemia and impaired glucose metabolism are thought to play a role. Read More

View Article and Full-Text PDF

Thiophene-2-carboxamide derivatives of anthraquinone: A new potent antitumor chemotype.

Eur J Med Chem 2021 Oct 24;221:113521. Epub 2021 May 24.

Blokhin Cancer Center, 24 Kashirskoye Shosse, Moscow, 115478, Russia; Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow, 119021, Russia.

The anthraquinone scaffold has long been known as a source of efficacious antitumor drugs. In particular, the various chemical modifications of the side chains in this scaffold have yielded the compounds potent for the wild type tumor cells, their counterparts with molecular determinants of altered drug response, as well as in vivo settings. Further exploring the chemotype of anticancer heteroarene-fused anthraquinones, we herein demonstrate that derivative of anthra[2,3-b]thiophene-2-carboxamide, (compound 8) is highly potent against a panel of human tumor cell lines and their drug resistant variants. Read More

View Article and Full-Text PDF
October 2021

Gata2-L359V impairs primitive and definitive hematopoiesis and blocks cell differentiation in murine chronic myelogenous leukemia model.

Cell Death Dis 2021 Jun 2;12(6):568. Epub 2021 Jun 2.

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai, China.

GATA2, a key transcription factor in hematopoiesis, is frequently mutated in hematopoietic malignancies. How the GATA2 mutants contribute to hematopoiesis and malignant transformation remains largely unexplored. Here, we report that Gata2-L359V mutation impeded hematopoietic differentiation in murine embryonic and adult hematopoiesis and blocked murine chronic myeloid leukemia (CML) cell differentiation. Read More

View Article and Full-Text PDF

Bis-Bibenzyls from the Liverwort and Their Biological Activity.

Plants (Basel) 2021 May 26;10(6). Epub 2021 May 26.

Institute of Botany and Botanical Garden "Jevremovac", Faculty of Biology, University of Belgrade, 11000 Begrade, Serbia.

Based on previous investigations where bis-bibenzyls isolated from liverworts showed various biological activities (cytotoxic, antimicrobial, and antiviral), we investigated their cytotoxic activity in several human cancer cell lines. From the methylene-chloride/methanol extract of the liverwort , three bis-bibenzyls of the perrottetin type were isolated, namely perrottetin E, 10'-hydroxyperrottetin E, and 10,10'-dihydroxyperrottetin E. The last two were found for the first time in this species. Read More

View Article and Full-Text PDF

Anti-Leukemic Properties of Aplysinopsin Derivative EE-84 Alone and Combined to BH3 Mimetic A-1210477.

Mar Drugs 2021 May 21;19(6). Epub 2021 May 21.

Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08626, Korea.

Aplysinopsins are a class of marine indole alkaloids that exhibit a wide range of biological activities. Although both the indole and N-benzyl moieties of aplysinopsins are known to possess antiproliferative activity against cancer cells, their mechanism of action remains unclear. Through in vitro and in vivo proliferation and viability screening of newly synthesized aplysinopsin analogs on myelogenous leukemia cell lines and zebrafish toxicity tests, as well as analysis of differential toxicity in noncancerous RPMI 1788 cells and PBMCs, we identified EE-84 as a promising novel drug candidate against chronic myeloid leukemia. Read More

View Article and Full-Text PDF

The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment.

Case Rep Hematol 2021 3;2021:5518727. Epub 2021 May 3.

Department of Hematology Nephrology and Rheumatology, Akita University, 1-1 Hondo 1-Chome, Akita 010-8543, Japan.

In the era of tyrosine kinase inhibitor (TKI) treatment, its effectiveness in treating chronic myelogenous leukemia (CML) has been improved, ensuring the same prognosis as that of healthy people of the same age. However, there are some patients with de novo blast crisis that undergoes acute conversion from the time of diagnosis and does not respond to TKI treatment, especially in the older patients. Here, we present a case of an older patient with de novo lymphoid crisis who was first treated with a combination of TKI and chemotherapy, but it was difficult to maintain a durable deep molecular response (DMR). Read More

View Article and Full-Text PDF

Screening and identification of key genes in imatinib-resistant chronic myelogenous leukemia cells: a bioinformatics study.

Hematology 2021 Dec;26(1):408-414

State Key Laboratory of Fine Chemicals, School of Life Science and Technology, Dalian University of Technology, Dalian, People's Republic of China.

Background: Chronic myelogenous leukemia (CML) is one of the most common cancers in the world. Imatinib is one of the most effective therapeutic strategies to inhibit the BCR-ABL tyrosine Kinase in patients with CML, but resistance is increasingly encountered.

Material And Methods: Microarray data GSE7114, GSE92624 and GSE97562 were downloaded and analyzed from Gene Expression Omnibus (GEO) to identify the candidate genes in the imatinib-resistant CML cells. Read More

View Article and Full-Text PDF
December 2021

Chronic Myeloid Leukaemia with Sudden Bilateral Deafness and Leg Ulcer Associated with Hydroxyurea Therapy.

West Afr J Med 2021 May;38(5):502-506

Department of Internal Medicine, Faculty of Clinical Medicine, College of Health Sciences, Ebonyi State University, Abakaliki, Ebonyi State, Nigeria.

Deafness occurs rarely in patients with chronic myeloid leukaemia. Hydroxyurea-induced leg ulcer has been found in patients on long-term hydroxyurea therapy. We present a 53 year old man who developed spontaneous bilateral deafness shortly after he was diagnosed with chronic myeloid leukaemia and subsequently developed hydroxyurea induced leg ulcer in the course of treatment. Read More

View Article and Full-Text PDF

Tanshinone I inhibited growth of human chronic myeloid leukemia cells via JNK/ERK mediated apoptotic pathways.

Braz J Med Biol Res 2021 24;54(8):e10685. Epub 2021 May 24.

The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.

Tanshinone I (Tan I) is one of the main bioactive ingredients derived from Salvia miltiorrhiza Bunge, which has exhibited antitumor activities toward various human cancer cells. However, its effects and underlying mechanisms on human chronic myeloid leukemia (CML) cells still require further investigation. This study determined the effects and mechanisms of anti-proliferative and apoptosis induction activity induced by Tan I against K562 cells. Read More

View Article and Full-Text PDF

WeChat as a Platform for Problem-Based Learning Among Hematological Postgraduates: Feasibility and Acceptability Study.

J Med Internet Res 2021 May 25;23(5):e16463. Epub 2021 May 25.

Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.

Background: Hematological medicine is a practical discipline that is difficult to study. Problem-based learning (PBL) is an innovative student-centered teaching method wherein students define their own learning objectives from clinically based problems. Considering that WeChat is the most popular communication app in China, we selected it as a new platform for online PBL to reduce the limitations of traditional PBL in hematology teaching. Read More

View Article and Full-Text PDF

Eye: the door to undiagnosed chronic myeloid leukaemia.

BMJ Case Rep 2021 May 24;14(5). Epub 2021 May 24.

Vitreoretinal Services, LV Prasad Eye Institute Bhubaneswar Campus, Bhubaneswar, Odisha, India.

Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm that can present in varied ways from incidental finding on haemogram to symptomatic presentation such as splenomegaly. We report an interesting case of a 22-year-old man who presented with loss of vision in right eye for 1 month. There were no pre-existing ocular or systemic diseases. Read More

View Article and Full-Text PDF

A unique three-way Philadelphia chromosome variant t(4;9;22)(q21;q34;q11.2) in a newly diagnosed patient with chronic phase chronic myeloid leukemia: a case report and review of the literature.

J Med Case Rep 2021 May 25;15(1):285. Epub 2021 May 25.

Department of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University faculty of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.

Background: Chronic myeloid leukemia is a hematologic malignancy associated with the fusion of two genes: BCR and ABL1. This fusion results from a translocation between chromosomes 9 and 22, which is called the Philadelphia chromosome. Although the Philadelphia chromosome is present in more than 90% of patients with chronic myeloid leukemia, 5-8% of patients with chronic myeloid leukemia show complex variant translocations. Read More

View Article and Full-Text PDF

Discovery of a Candidate Containing an ()-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.

J Med Chem 2021 06 19;64(11):7434-7452. Epub 2021 May 19.

Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China.

BCR-ABL kinase inhibition is an effective strategy for the treatment of chronic myeloid leukemia (CML). Herein, we report compound , bearing a difluoro-indene scaffold, as a novel potent pan-inhibitor against BCR-ABL mutants, including the most refractory T315I mutant. As the privileged ()-isomer compared to its ()-isomer , exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABL BaF3 cells, with IC values of 0. Read More

View Article and Full-Text PDF

Cutaneous polyarteritis nodosa presenting as a paraneoplastic phenomenon in chronic myelogenous leukemia.

JAAD Case Rep 2021 Jun 1;12:25-28. Epub 2021 Apr 1.

Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

View Article and Full-Text PDF

Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma.

JCI Insight 2021 Jun 22;6(12). Epub 2021 Jun 22.

Division of Gastroenterology and Hepatology and.

Hepatocellular carcinoma (HCC) is the sixth most common and the fourth most deadly cancer worldwide. The development cost of new therapeutics is a major limitation in patient outcomes. Importantly, there is a paucity of preclinical HCC models in which to test new small molecules. Read More

View Article and Full-Text PDF

Intracellular ROS profile in hematopoietic progenitors of MDS patients: association with blast count and iron overload.

Hematology 2021 Dec;26(1):88-95

Biological Sciences, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Canada.

Reactive oxygen species (ROS) are under scrutiny as a participant in the pathophysiology of myelodysplastic syndrome (MDS) and the progression of MDS to acute myeloid leukemia (AML). Measurement of intracellular ROS (iROS) is particularly important since iROS is a direct indicator of cellular health and integrity. We developed a technique to measure standardize iROS (siROS) level in lymphocytes and bone marrow (BM) CD34 hematopoietic progenitors using the fluorescent probe dichlorofluorescein (DCF). Read More

View Article and Full-Text PDF
December 2021

A clinical appraisal of chronic myeloid leukaemia (CML)-related death and CML-specific death-Are they synonymous?

Int J Clin Pract 2021 Jun;75(6):e14217

Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

View Article and Full-Text PDF